Key Points
- Director Julius Knowles sold 2,625 shares of Keros Therapeutics on June 4 at an average price of $10.73, totaling about $28,166. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Keros Therapeutics stock was down about 2.9% and opened at $10.00, near its 52-week low of $9.79. The company has a market cap of about $197.9 million and remains well below its 52-week high of $22.55.
- The company recently reported a wider-than-expected loss, posting EPS of -$1.21 versus expectations of -$1.02, on revenue of just $0.37 million. Analysts currently rate the stock a Hold on average, with a consensus price target of $20.40.
Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) Director Julius Knowles sold 2,625 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the sale, the director directly owned 10,958 shares of the company's stock, valued at $117,579.34. This trade represents a 19.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Keros Therapeutics Stock Down 2.9%
Shares of NASDAQ:KROS opened at $10.00 on Tuesday. Keros Therapeutics, Inc. has a 52-week low of $9.79 and a 52-week high of $22.55. The company has a 50 day moving average of $11.31 and a two-hundred day moving average of $15.10. The company has a market capitalization of $197.90 million, a price-to-earnings ratio of -3.32 and a beta of 0.94.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. The firm had revenue of $0.37 million during the quarter, compared to analyst estimates of $1.93 million. On average, equities analysts anticipate that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current year.
Institutional Investors Weigh In On Keros Therapeutics
A number of institutional investors have recently made changes to their positions in KROS. AQR Capital Management LLC bought a new stake in shares of Keros Therapeutics in the 1st quarter valued at approximately $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Keros Therapeutics by 15.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company's stock valued at $227,000 after acquiring an additional 2,982 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Keros Therapeutics by 38.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company's stock valued at $7,547,000 after acquiring an additional 205,022 shares during the last quarter. Creative Planning increased its holdings in shares of Keros Therapeutics by 40.2% in the 2nd quarter. Creative Planning now owns 24,226 shares of the company's stock valued at $323,000 after acquiring an additional 6,948 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Keros Therapeutics by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 51,815 shares of the company's stock valued at $692,000 after acquiring an additional 7,146 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of research firms have recently weighed in on KROS. Weiss Ratings downgraded shares of Keros Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research report on Friday, May 15th. Wall Street Zen downgraded shares of Keros Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, May 16th. Finally, Wells Fargo & Company decreased their price target on shares of Keros Therapeutics from $23.00 to $20.00 and set an "overweight" rating for the company in a research report on Thursday, March 5th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $20.40.
View Our Latest Stock Report on KROS
About Keros Therapeutics
(
Get Free Report)
Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.
The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
